MedTrace Logo

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

NCT06662162 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-04

No results posted yet for this study

Summary

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.

Participants will:

* Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months.
* Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.

Conditions

  • Age-Related Macular Degeneration
  • Age-related Macular Degeneration (ARMD)
  • Intermediate AMD
  • Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions

DEVICE

i-Lumen AMD

i-Lumen AMD transpalpebral microcurrent stimulation system

Sponsors & Collaborators

  • i-Lumen Scientific, Inc.

    collaborator INDUSTRY

  • i-Lumen Scientific AUS PTY LTD

    lead INDUSTRY

Principal Investigators

  • Meredith Mundy · i-Lumen Scientific AUS PTY LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-07
Primary Completion
2027-03-31
Completion
2029-12-31
FDA Device
Yes

Countries

  • United States
  • Australia
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06662162 on ClinicalTrials.gov